The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Oncology (Switzerland)

Volumn 90, Issue 2, 2016, Pages 69-78

  Mahammedi, Hakim ^a   Planchat, Eloise ^a,b,c   Pouget, Mélanie ^a,b,c   Durando, Xavier ^a   Curé, Hervé ^e   Guy, Laurent ^d   Van Praagh, Isabelle ^a   Savareux, Laurent ^f   Atger, Marc ^f   Bayet Robert, Mathilde ^a   Gadea, Emilie ^a,c   Abrial, Catherine ^a,c   Thivat, Emilie ^a,c   Chollet, Philippe ^a,b   Eymard, Jean Christophe ^e  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^f Clinique de la Chataigneraie   (France)

Author keywords

Castration resistant prostate cancer; Curcumin; Docetaxel; Neuroendocrine markers; Phase II

Indexed keywords

CHROMOGRANIN A; CURCUMIN; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NEURON SPECIFIC ENOLASE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ENOLASE; TAXOID;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; EVENING DOSAGE; FEBRILE NEUTROPENIA; FOLLOW UP; GERIATRIC ASSESSMENT; GERIATRIC DEPRESSION SCALE; GLEASON SCORE; HUMAN; INFLUENZA; MALE; MICROCAPSULE; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NUTRITIONAL ASSESSMENT; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREMEDICATION; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE; UNGUAL TOXICITY; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOGRANIN A; CURCUMIN; GERIATRIC ASSESSMENT; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PILOT PROJECTS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84955585899     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000441148     Document Type: Article

References (37)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
2. Bemis DL, Katz AE, Buttyan R: Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 2006; 15: 1191-1200.
3. Thangapazham RL, Sharma A, Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 2006; 8:E443-E449.
4. Gupta SC, Patchva S, Aggarwal BB: Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15: 195-218.
5. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol Pharmacol 2006; 69: 195-206.
6. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB: Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20: 7597-7609.
7. Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S: Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21/WAF1/CIP1. Cell Cycle 2007; 6: 2953-2961.
8. Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005; 280: 20059-20068.
9. Bae M-K, Kim S-H, Jeong J-W, Lee YM, Kim H-S, Kim S-R, et al: Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006; 15: 1557-1562.
10. Choi HY, Lim JE, Hong JH: Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis 2010; 13: 343-349.
11. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005; 280: 6301-6308.
12. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP: Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 2005; 113: 490-498.
13. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/ Akt/NFκB pathway. Cancer Lett 2008; 259: 111-118.
14. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al: Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010; 70: 1127-1133.
15. Chen WT-L, Yang T-S, Chen H-C, Chen H-H, Chiang H-C, Lin T-C, et al: Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer. Nutr Res 2014; 34: 585-594.
16. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P: A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014; 17: 180-186.
17. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabineresistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-164.
18. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499.
19. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010; 9: 8-14.
20. Vashchenko N, Abrahamsson P-A: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-155.
21. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992; 70: 254-268.
22. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S: Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008; 8: 21.
23. Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF: Serum chromogranin-A in advanced prostate cancer. BJU Int 2001; 88: 790-796.
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
25. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
26. Galsky MD, Vogelzang NJ: Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010; 21: 2135-2144.
27. Eymard J-C, Priou F, Zannetti A, Ravaud A, Lepille D, Kerbrat P, et al: Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007; 18: 1064-1070.
28. Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, et al: Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008; 102: 1080-1085.
29. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-2900.
30. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
31. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al: Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castrationresistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011; 22: 2476-2481.
32. Loriot Y, Massard C, Gross-Goupil M, Palma MD, Escudier B, Bossi A, et al: Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009; 20: 703-708.
33. Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI: Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol Stockh Swed 2002; 41: 668-674.
34. Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay J-O: Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006; 175: 1347-1352.
35. Cabrespine-Faugeras A, Bayet-Robert M, Bay J-O, Chollet P, Barthomeuf C: Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutr Cancer 2010; 62: 148-153.
36. Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E, et al: The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hell J Nucl Med 2009; 12: 234-237.
37. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25: 42-46.